High-risk molecules or insufficient scientific data?

When I was invited to author an ethics policy piece on the approach to high-risk molecules as a contribution to the theme of Innovation in Drug Development of this Clinical Pharmacology & Therapeutics issue, I thought there was a need to evaluate whether questioning the transition from preclinical to clinical development after the TGN 1412 serious adverse event may freeze the development of innovating tools in drug development.